Proteros and Boehringer Ingelheim to collaborate

Under the terms of the agreement, which will run for 18 months, Proteros will receive research funding fees and success payments for the generation and analyses of protein-ligand-structures of hits and evolved chemical entities from in-house Boehringer Ingelheim programs.

Torsten Neuefeind, CEO of Proteros, said: “By taking advantage of Proteros’ experience and the industrialized processes enabling time- and cost-efficient protein-ligand-structure analyses, Boehringer Ingelheim complements its internal capabilities with our external expertise and access flexible resources.”